From GlobeNewswire: 2024-11-13 10:30:00

Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: 15+ companies are advancing treatments to improve the landscape. Rising prevalence from infections, autoimmune diseases, and COPD drives market growth. Awareness boosts early diagnosis and treatment. New therapies and mucolytics expand options. Pharmaceutical R&D aims to meet unmet medical needs.

DelveInsight’s report highlights over 15 active companies developing 15+ non-cystic fibrosis bronchiectasis drugs. Key players like Zambon SpA, Insmed, Armata Pharmaceuticals, and others are working on promising therapies like Colistimethate sodium, Benralizumab, and Brensocatib. Recent successes include Armata’s Phase II study enrollment and Insmed’s positive Phase III results.

The NCFB pipeline report offers detailed profiles of pipeline assets, clinical and non-clinical stage drugs, and driving factors. Companies like Boehringer Ingelheim, Renovion, and NovaBiotics are evaluating new treatments. Various mechanisms like cystic fibrosis transmembrane conductance regulator stimulants and PcrV inhibitors are being explored in clinical trials.

Non-Cystic Fibrosis Bronchiectasis is a chronic lung condition characterized by airway damage and mucus buildup. Causes include infections, autoimmune diseases, and idiopathic factors. Symptoms range from chronic cough to respiratory failure. Diagnosis involves imaging studies and lung function tests. Treatment aims to control symptoms, reduce infections, and improve lung health.

A snapshot of emerging NCFB drugs includes Benralizumab, Brensocatib, and AP-PA02 in various phases of development. Companies like AstraZeneca and Insmed are leading with innovative therapies. The report provides a comprehensive view of the NCFB pipeline, detailing mechanisms of action and routes of administration for each drug.

DelveInsight’s Pharma Competitive Intelligence Service provides real-time insights on competitors and market trends. Reports cover various therapeutic areas and indications, helping clients stay ahead of the competition. Other consulting services include healthcare conference coverage, pipeline assessments, and due diligence case studies. DelveInsight is a leading life sciences-focused business consultant and market research firm.



Read more at GlobeNewswire: Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over